How would you treat a patient with a small (<0.5 cm) node negative, grade 3 BRCA1 mutated triple negative breast cancer?
An article (BRCA mutation and outcome in BC. Ellen Copson, et al. Lancet Oncol. 2018) showed G3, BRCA+ breast cancer had poorer prognosis compared to BRCA- breast cancer in a subgroup analysis.
This is not a typical case for oncotype but is it worthwhile to obtain oncotype or Mammaprint to further guide the decision?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Michigan Medical School
Answered on
In the recently published POSH trial by Copson et al (Lancet Oncology), the investigators examined outcomes in a cohort of women age 40 or younger newly diagnosed with breast cancer. In the overall cohort of 2733 women, 12% had BRCA mutations. After a median follow-up of 8.2 years, there was no sign...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Warren Alpert Medical School of Brown University
Answered on
As the POSH trial included very few patients with tumors this size (median size was 2.2 cm, 95% 1.5-3.1 cm) and very few (2%) TNBC patients who did not receive chemotherapy (adjuvant or neoadjuvant), its results are applicable to this case only to reassure us (and the patient) that patients with BRC...
Join for free or sign in to see the full answer